Mike Trower has more than 25 years’ drug discovery and development experience in pharmaceutical and biotech industries.
He is a joint founder of NeRRe Therapeutics Ltd, and holds the positions of Chief Scientific Officer and Chief Operating Officer in the company. Mike was deeply involved in the acquisition of the Company’s neurokinin antagonist portfolio from GSK, where he was previously VP & Head of the External Drug Discovery Group in the Neurosciences Centre for Excellence for Drug Discovery (CEDD).
In this position he had responsibility for defining & implementing the CEDD externalisation strategy and advancing a portfolio of preclinical and clinical pipeline assets. He has expert knowledge of the neurosciences, and neuronal hypersensitivity disorders relating to neurokinin receptor system biology.
Mike has BSc (Hons) and PhD degrees in biological sciences and has held post-doctoral positions at DuPont Inc in Delaware, US, and at the Medical Research Council in Cambridge, UK, under the Nobel laureate Professor Sydney Brenner. He joined Glaxo Group Research (a GSK legacy company) in 1992.